Insider Selling: Artivion, Inc. (NYSE:AORT) CAO Sells 12,430 Shares of Stock

by · The Cerbat Gem

Artivion, Inc. (NYSE:AORT – Get Free Report) CAO Amy Horton sold 12,430 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total transaction of $325,417.40. Following the transaction, the chief accounting officer now directly owns 139,989 shares of the company’s stock, valued at $3,664,912.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Artivion Trading Down 1.6 %

AORT opened at $25.92 on Friday. The company has a quick ratio of 4.04, a current ratio of 5.63 and a debt-to-equity ratio of 1.07. Artivion, Inc. has a 52 week low of $12.16 and a 52 week high of $29.24. The stock has a market cap of $1.08 billion, a PE ratio of -108.00 and a beta of 1.74. The business has a 50 day moving average of $25.73 and a 200-day moving average of $24.04.

Artivion (NYSE:AORT – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.03 by $0.04. Artivion had a positive return on equity of 3.81% and a negative net margin of 2.22%. The business had revenue of $98.02 million during the quarter, compared to analyst estimates of $97.70 million. Equities research analysts predict that Artivion, Inc. will post 0.2 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on AORT shares. Oppenheimer upped their price target on Artivion from $25.00 to $30.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Lake Street Capital upped their target price on Artivion from $28.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, July 2nd. Needham & Company LLC reiterated a “buy” rating and issued a $30.00 price target on shares of Artivion in a report on Friday, September 27th. Finally, Stifel Nicolaus upped their price objective on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a report on Friday, September 13th.

Get Our Latest Report on AORT

Institutional Trading of Artivion

Institutional investors have recently bought and sold shares of the company. Wasatch Advisors LP lifted its position in Artivion by 108.8% in the 1st quarter. Wasatch Advisors LP now owns 1,083,568 shares of the company’s stock valued at $22,928,000 after acquiring an additional 564,549 shares in the last quarter. Perceptive Advisors LLC lifted its holdings in shares of Artivion by 4.7% during the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock valued at $71,658,000 after purchasing an additional 124,725 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of Artivion by 8.1% during the first quarter. First Eagle Investment Management LLC now owns 570,242 shares of the company’s stock valued at $12,066,000 after buying an additional 42,705 shares during the last quarter. Vanguard Group Inc. increased its holdings in Artivion by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after buying an additional 33,982 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Artivion in the 3rd quarter worth about $450,000. 86.37% of the stock is owned by hedge funds and other institutional investors.

Artivion Company Profile

(Get Free Report)

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.

Recommended Stories